Abbott Laboratories (ABT)

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy...

UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard.  In a note to clients on Tuesday, the analysts wrote that healthcare equipment has ha...

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristoc...

ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.

In the closing of the recent trading day, Abbott (ABT) stood at $133.89, denoting a -1.47% move from the preceding trading day.

President Donald Trump's trade policies have introduced plenty of volatility to the stock market this year. Steeper tariffs could impact consumer spending and the broader economy in ways that could ha...

It's often said that cash is king, but I would take it one step further. Abbott Laboratories is an AA-rated Dividend King with healthy growth prospects but a rich valuation. I'm waiting for a pullback...

Forget the dividend darlings everyone already owns -- the real money in income investing comes from companies raising their payouts faster than inflation while keeping enough cash to reinvest in growt...

ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.